CytomX Therapeutics, Inc. (CTMX) Stock Price, Financial Report, & Fundamental AnalysisNASDAQ:CTMX
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States.
CytomX Therapeutics, Inc. Fundamental Analysis
CTMX has positive revenue for last 5 years
Small market capitalization. Market capitalization is less than 2bn USD
CTMX has never had growing revenue.
Net Income Growth
CTMX has never had growing net income.
Price to Book (PBV) Ratio
Overvalued price-to-book. CTMX stock price is overvalued by more than 2x the price-to-book value.
CTMX never has positive net income for 2 years.
Debt-Equity Ratio (DER)
CTMX debt is 6.95x it's equity.
CTMX has low dividend yield (0%).
Return of Assets
CTMX has low return of asset (-43.09%).
Return of Equity
CTMX has low return of equity (-166.29%).
Return of Invested Capital
CTMX has low ROIC.
CytomX Therapeutics, Inc. Financials
Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.
Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.
- 69,573,000 USD
- 153,354,000 USD
- Net Income
- -83,609,000 USD
- Profit Margin
A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.
- Free Cash Flow
- -120,640,000 USD
Liquidity & Solvency
Solvency refers to an company's capacity to meet its long-term financial commitments. Liquidity refers to an company's ability to pay short-term obligations. The term also refers to a company's capability to sell assets quickly to raise cash.
Short Term Liabilities
Long Term Liabilities
|Dividend Payout Ratio (DPR)||0%|
|Dividend Payout Ratio (DPR)||0%|
|Dividend per Share||0,00 USD|
|Price to Earning (PER)||-1.1x|
|Price to Earning-Growth (PEG)||0x|
|Price to Book Value (PBV)||0x|
|Debt-Equity Ratio (DER)||695.43%|
|Net Profit Margin (NPM)||-135.65%|
|Return of Assets (ROA)||-43.09%|
|Return of Equity (ROE)||-166.29%|
|Return on Capital Employed (ROCE)||-76.92%|
|Days of Sales Outstanding (DSO)||8.69|
|Days of Inventory Outstanding (DIO)||0|
|Days Payable Outstanding (DPO)||0|
|Operating Cycle (OC)||0|
|Cash Conversion Cycle (CCC)||0|
CytomX Therapeutics, Inc. Executives
- CEO Name
- DR. Sean McCarthy
CytomX Therapeutics, Inc. Profile
About CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
- Company name
- CytomX Therapeutics, Inc.
- NASDAQ Global Select
151 Oyster Point Blvd Ste 400
South San Francisco